Key result
Intravenous dexmedetomidine administration during off-pump coronary artery bypass grafting significantly stabilized hemodynamics and reduced pro-inflammatory factors (IL-6, TNF-α, and CRP) compared to placebo.
Why the study?
To determine the effect of dexmedetomidine on hemodynamic changes and inflammatory responses in patients undergoing off-pump coronary artery bypass grafting.
Does intraoperative intravenous dexmedetomidine improve hemodynamic stability and reduce inflammatory responses in patients undergoing off-pump coronary artery bypass grafting?
RCT (n=239)
Double-blind
Sealed envelopes with serial numbers
No
Does intraoperative intravenous dexmedetomidine improve hemodynamic stability and reduce inflammatory responses in patients undergoing off-pump coronary artery bypass grafting?
p-value: p=<0.05
Intraoperative dexmedetomidine infusion during off-pump coronary artery bypass grafting stabilizes hemodynamics and reduces the acute pro-inflammatory response.
No takes yet. Share an insight, caveat, or question.
May support dexmedetomidine for hemodynamic stability in OPCABG; leaves open confirmation in larger outcome trials.
Zhai et al. (2020) conducted an RCT in Coronary artery disease requiring off-pump coronary artery bypass grafting (OPCABG) (n=239). Dexmedetomidine vs. Physiological saline was evaluated on Hemodynamic parameters (heart rate and mean arterial pressure) and inflammatory indices (IL-6, TNF-α, CRP) (p=<0.05). Intravenous dexmedetomidine administration during off-pump coronary artery bypass grafting significantly stabilized hemodynamics and reduced pro-inflammatory factors (IL-6, TNF-α, and CRP) compared to placebo.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: